AXNX - Axonics Modulation Technologies GAAP EPS of -$0.19 revenue of $70.7M

2023-05-01 17:08:29 ET

• Axonics Modulation Technologies press release ( NASDAQ: AXNX ): Q1 GAAP EPS of -$0.19.
• Revenue of $70.7M (+46.0% Y/Y).
• Gross margin was 74.3% in 1Q23 compared to 68.7% in the prior year period.
• Operating expenses were $66.9 million in 1Q23 and included a $1.8 million
• Adjusted EBITDA was $0.9 million in 1Q23 compared to an adjusted EBITDA loss of $13.4 million in the prior year period.
• Net loss was $9.2 million in 1Q23 compared to a net loss of $22.7 million in the prior year period.
• Cash, cash equivalents and short-term investments were $357 million as of March 31, 2023.

• Axonics has updated its fiscal year 2023 revenue guidance as follows:

• Total company revenue of $348 million, an increase of 27% compared to fiscal year 2022.

• This compares to initial fiscal year 2023 revenue guidance of $342 million.

• Sacral neuromodulation revenue of $280.5 million, an increase of 26% compared to fiscal year 2022.

• Bulkamid revenue of $67.5 million, an increase of 31% compared to fiscal year 2022.

For further details see: